Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
Annals of oncology : official journal of the European Society for Medical Oncology·2020
NCI-EORTC-AACR--11th Symposium on New Drugs in Cancer Therapy: Gene therapy and new drugs. 7-10 November 2000, Amsterdam, The Netherlands.
IDrugs : the investigational drugs journal·2005
Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer.
Current opinion in molecular therapeutics·2001
Thymitaq (Zarix).
Current opinion in investigational drugs (London, England : 2000)·2001
In silico and In vitro studies of EGFR kinase and Anilide derivatives as inhibitors against Breast Cancer.
Biotechnology notes (Amsterdam, Netherlands)·2026
Comparative metabolomic and protective effects of Quercus leucotrichophora leaf and acorn extracts against doxorubicin-induced oxidative and inflammatory injury.
Journal of diabetes and metabolic disorders·2026